Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for lorlatinib (brand name: Lorb···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：72
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for its targeted anticancer therapy Lorbrena (lor···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：53
On January 28, 2022, Pfizer Inc. announced that the European Commission (EC) had approved the marketing authorization of lorlatinib (LORVIQUA®, LORBRENA®) as a monotherapy for the ···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：55
At present, the core objective of research related to ponatinib is to improve its medication safety and therapeutic efficacy.Which drugs interact with Ponatinib?Combination use of ···【more】
Article source：Captain MedicineRelease date：2026-01-21Recommended：58
Patients should maintain a written list of all prescription drugs, over-the-counter (OTC) medications, vitamins, minerals, and dietary supplements they are taking. This list must b···【more】
Article source：Captain MedicineRelease date：2026-01-21Recommended：60
This medicine may cause fluid retention and heart failure. If you experience rapid weight gain, chest pain or tightness, extreme fatigue, difficulty breathing, or swelling of the h···【more】
Article source：Captain MedicineRelease date：2026-01-21Recommended：55
Ponatinib exerts its therapeutic effect by inhibiting cancer cell proliferation and is indicated for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia.What···【more】
Article source：Captain MedicineRelease date：2026-01-21Recommended：44
Ponatinib is a targeted therapy indicated for the treatment of specific types of leukemia, such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphob···【more】
Article source：Captain MedicineRelease date：2026-01-21Recommended：74
Ponatinib is a targeted therapy for the treatment of specific types of leukemia. Its common adverse effects include cardiovascular disorders (such as hypertension and thrombosis), ···【more】
Article source：Captain MedicineRelease date：2026-01-21Recommended：55
Ponatinib is indicated for the treatment of specific types of chronic myeloid leukemia (CML; a type of white blood cell cancer) in patients who no longer benefit from other CML med···【more】
Article source：Captain MedicineRelease date：2026-01-21Recommended：52
Ponatinib is an oral tyrosine kinase inhibitor primarily indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leuk···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：58
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) primarily indicated for the treatment of specific types of leukemia, such as Philadelphia chromosome-positive chroni···【more】
Article source：Captain MedicineRelease date：2026-01-20Recommended：92
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1612025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4002024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1552025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1882025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1692025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1652025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
